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Abstract
NIPSNAP1 (4-nitrophenyl phosphatase domain and non-neuronal SNAP25-like protein
homolog1) is an evolutionarily conserved mitochondrial protein that interacts with the
cytoplasmic domain of the Alzheimer’s Disease (AD) amyloid precursor protein (APP).
NIPSNAP1 interaction with APP may contribute to mitochondrial dysfunction and possibly to
neurodegeneration associated with AD. To investigate the molecular and cellular role of
NIPSNAP1, we created a NIPSNAP1 knockdown cell line using shRNA lentiviral strategy.
Immunoblot analysis showed that one shRNA construct reduced NIPSNAP1 protein levels by
approximately 85%. Reduction of NIPSNAP1 protein required at least 10 days after shRNA
lentiviral transduction, suggesting that NIPSNAP1 protein is highly stable in hepatoma cells. In
addition, NIPSNAP1 deficiency reduced Reactive Oxygen Species (ROS), suggesting that
NIPSNAP1 regulates mitochondrial function. Taken together, this work establishes a NIPSNAP1
knock-down cell line in which detailed molecular and cellular studies can be conducted in the
future.
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Introduction
Hallmarks of Alzheimer’s Disease
Alzheimer disease is progressive neurodegenerative disease that results in memory
impairment and loss of cognitive functions. There are two types of Alzheimer disease; an early
on-set which affects people below the age of 65 and a late on-set sporadic form which affect
individuals over the age of 65. Mutations Amyloid Precursor Protein (APP), Presenilin 1(PS1),
and Presenilin (PS2) are strongly associated with early onset of AD (Grigorenkoa et al. 2007).
All these mutations result in abnormal cleavage of APP and accumulation of the amyloid
peptides.
Alzheimer disease brain is characterized by the formation of extracellular amyloid
plaques and intracellular neurofibrillary tangles. Amyloid plaques are initiated by the
aggregation of A peptides (O'Brien et al., 2011, Kant et al. 2015). PS1 and PS2 are subunits of
-secretase complex and are responsible for catalyzing the cleavage of APP. Mutations in PS1
and PS2 modify the cleavage location on APP and produce A peptides of different lengths
ranging from 38 to 43 amino acids long (Chow et al., 2010). In contrast, neurofibrillary tangles
are formed by intracellular aggregation of tau proteins. Tau is a brain-specific axon-enriched
microtubule-associated protein that regulates the stability of tubulin assemblies. The
accumulation of amyloid plaques and tau tangles are toxic and damage neurons by impairing
synaptic function, preventing communication between dendrites and axons of neighboring
neurons leading to neuronal degeneration.
APP is proteolytically processed by three different secretase complexes: α-secretase, βsecretase and -secretase enzymes. The site of cleavage by α-secretase and β-secretase is within
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the transmembrane domain of APP and results in the release of N-terminal fragments sAPP- α
and sAPP- β, respectively. Upon cleavage, the extracellular domain can function in some cellular
processes such as synapse formation, neurite outgrowth, cellular growth (O'Brien et al., 2011,
Kant et al., 2015). In addition, α-secretase and β-secretase cleavage of APP produce C-terminal
fragments CTF83 and CTF99, respectively (Chow et al., 2010). Finally, -secretase can further
process CTF83 and CTF99 to produce the extra-membrane fragments p3 and amyloid beta
peptides (A ), respectively, while the APP Intracellular Domain (AICD) is released into the
cytoplasm. AICD is conserved among APP family members and has been shown to interact with
a variety of different intracellular proteins (Kant et al. 2015).

APP intracellular domain Interacting Proteins
Recent studies have suggested that the intracellular domain of APP (AICD) might have a
profound role in the pathology of Alzheimer’s disease (Muller, T., et al 2008, Li et al., 2015,
Ghosal et al., 2016, Goiran et al., 2017). Transgenic mice that overexpress AICD exhibit
Alzheimer like symptoms such as accumulation of Tau, synaptic dysfunction and memory
impairment (Tamayev, et al 2012). It has been shown that intracellular AICD translocates in to
the nucleus and interact with transcription factors to control gene expression (Kant et al. 2015).
One downstream target gene whose expression is regulated by AICD is PINK-1 (Goiran et al.,
2017), which is involved in mitochondrial autophagy. PINK-1 and Parkin are interplay proteins
that are involved in mitophagy either dependently or independently from each other (Alves da
Costa et al., 2018) Parkin upregulate the expression of PS1 which in turn increase the generation
of AICD. AICD interacts with the transcription factor Foxo3 to increase PINK-1 expression
level (Wang et al., 2014, Goiran et al., 2017). Interestingly, PINK-1 recruits Parkin during
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mitochondrial depolarization to initiate mitophagy (Turban et al., 2017). Thus, Goiran et al.,
(2018) proposed that Parkin and PINK-1 are both involved in a feedback loop to regulate
mitochondrial homeostasis and that AICD is indirectly involved in this mechanism. Furthermore,
the C-terminal fragment of APP interacts with proteins that are involved in signaling and
trafficking pathways (Kant et al. 2015). For example, C-terminal fragments generated by secretase (C99) interact with multiple proteins of the Wnt-PNP receptor complex (Soldano et al.,
2013). Our group has shown that the AICD interacts with two mitochondrial proteins,
mitochondrial creatine kinase (uMtCK) (Li et al., 2006) and the novel 4-nitrophenylphosphatase
domain and non-neuronal synaptosomal associated protein 25 (SNAP25)-like protein homolog
(NIPSNAP1) (Tummala et al, 2010). Li et al., 2006 showed that the immature form of uMtCK,
containing putative mitochondrial targeting sequence, is stabilized upon overexpression of the Cterminal domain of APP family proteins. As in the case of uMtCK, NIPSNAP1 is also targeted to
the mitochondria through a mitochondrial targeting sequence located in its N-terminal region.
APP interaction with NIPSNAP1 is found to be important for the mitochondrial localization of
NIPSNAP1. Overexpression of APP seems to disrupt its localization (Tummala et al, 2010). In
addition, NIPSNAP1 colocalizes with the endogenous APP in the mitochondria. However, when
APP is overexpressed, NIPSNAP1 is found in the perinuclear regions. Taken together, these data
suggest a possible molecular connection between mitochondrial proteins and APP, which may
contribute to the mitochondrial dysfunction associated with AD.
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NIPSNAP1 Expression profile and localization.
NIPSNAP1 belongs to a family of proteins including NIPSNAP2 (also known as GBAS),
NIPSNAP3 (also known as NIPSNAP3B), and NIPSNAP4 (also known as NIPSNAP3A). The
Nipsnap1 gene was originally identified in C. elegans in a region that includes genes encoding
proteins with homology to 4-nitrosphenylphosphate (NIP) and synaptosomal associated protein
25 (SNAP) domains (Seroussi et al., 1998). Sequence alignment analysis shows high sequence
similarity between NIPSNAP1 and NIPSNAP2 and between NIPSNAP3 and NIPSNAP4,
suggesting that NIPSNAP1-NIPSNAP2 and NIPSNAP3-NIPSNAP4 may have redundant
functions. NIPSNAP1 has been shown to be highly expressed in brain, liver and kidney
(Tummala et al., 2010; Nautiyal et al., 2010). NIPSNAP1 expression in brain is neuron-specific
(Nautiyal et al., 2010). In contrast, NIPSNAP2 is mainly expressed in heart and brain (Wang et
al., 1998; Martherus et al., 2010) and NIPSNAP3 and NIPSNAP4 are expressed in brain, muscle
and testis (Buechler et al., 2004).
All NIPSNAP family proteins have a putative mitochondrial targeting sequence in their
N-terminal sequences (Abudu et al., 2019). Our group has confirmed NIPSNAP1 localization in
the mitochondria by immunofluorescence microscopy and by biochemical assays (Tummala et
al., 2010). Recently, NIPSNAP1 and 2 were found to localize to mitochondrial matrix and are
not membrane integrated proteins (Abudu et al., 2019). Interestingly, the same group
demonstrated that NIPSNAP1 and 2 have an internal mitochondrial targeting sequence that
translocates the protein from the matrix to the mitochondrial surface upon membrane
depolarization (Abudu et al., 2019). It has also been reported that NIPSNAP1 is localized to post
synaptic density fractions (Satoh et al, 2002). Furthermore, the mature form of NIPSNAP1 (29
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kDa) was shown to be present in synaptic membrane and cell surface by biotinylated cell surface
protein and immunofluorescence analysis (Okuda-Ashitaka et al., 2012). In line with its
distribution in the cell surface, NIPSNAP1 was found to interact with selective Ca2+ channel
TRPV6 and inhibits TRPV6 activity (Schoeber et al., 2008).

NIPSNAP1 role in Metabolic pathways
An early characterization of NIPSNAP1 function revealed that NIPSNAP1 directly
interact with the E2 subunit of pyruvate dehydrogenase (PDH) and α-ketoacid dehydrogenase
complex (BCKDC) (Islam 2010, Nauyital et al, 2010). The above observations were in line with
our group’s work in NIPSNAP1 gene network analysis (Ghoshal, et al., 2013). NIPSNAP1
correlated genes were found to be enriched in three KEGG pathways: pyruvate metabolism,
glycolysis and TCA cycle. Interestingly, NIPSNAP1 correlated genes that were enriched in all
three KEGG pathways are components of dehydrogenase complexes involved in energy
metabolism (Dlat, Dld, Pdh1a, Pdhb), suggesting an important role of NIPSNAP1 in metabolic
pathways.
Metabolomic profiling of brain and liver tissues from NIPSNAP1 deficient mice revealed
broad changes in the levels of metabolic intermediates compared to WT (Ghoshal, 2013). The
altered intermediates were involved in lipid, amino acid, nucleotide or carbohydrate metabolic
pathways. The branched chain amino acid (BCAA) valine was increased two fold in the liver of
NIPSNAP1 deficient mice. It’s worth noting that NIPSNAP1 deficiency didn’t significantly alter
pyruvate, lactate or BCAA isoleucine or leucine. In addition, they found a significant increase in
tryptophan and its metabolite 3-indoxyl sulphate (Ghoshal, 2013). The significance of this result
is that tryptophan metabolite 3-indoxyl sulfate can induce oxidative stress by decreasing the
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levels of the antioxidant, glutathione (Dou et al. 2007; Fujii et al. 2011). In fact, Ghoshal et al.,
(2014) found that NIPSNAP1 deficiency resulted in oxidative stress in the liver as indicated by
lower levels of reduced glutathione (GSH) in KD compared to WT.
Brain metabolomics studies of NIPSNAP1 deficient mice revealed an 8.74 fold increase
in adenosine 5’diphosphoribose (ADPR) level and a 2.15 fold increase in adenosine
monophosphate (AMP) (Goshal, 2013). ADPR is an ester monomer that can be linked together
by poly ADP ribose polymerase to form poly (ADP-ribose) polymer (PAR), which is considered
to be an important regulator of various cellular molecular processes (Cohen et al., 2018). ADPR
can activate the Ca2+ non-selective cation channel TRPM2 (Uchida et al. 2011). In addition, it
has been suggested that ADPR serves as a scaffold and recruits regulatory proteins that are
involved in gene regulation and DNA repair damage (Ryu et al. 2015). In addition, one study has
proposed a new hormone-dependent nuclear pathway that generates ATP from ADPR (Wright et
al., 2012). They reported that the hydrolase enzyme NUDIX5 catalyzes the direct conversion of
ADPR to ATP. Interestingly, a proteome analysis of PAR-binding proteins revealed that
NIPSNAP1 is one of the PAR-binding candidates (Wright et al., 2016). These results in
combination with our metabolic data suggest that NIPSNAP1 may play a role in ADPR-related
mechanisms.

NIPSNAP1 role in inflammatory signaling pathways
NIPSNAP1 seems to play a prominent role in signaling pathways involved in modulating
inflammatory responses (Okuda-Ashitaka et al., 2012; Okamoto et al., 2016; Yamamoto et al.,
2017). Early evidence of NIPSNAP1involvment in inflammatory responses showed that
NIPSNAP1 interacts with Nocistatin (NST) to inhibit N/OFQ-induced tactile pain allodynia
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(Okuda-Ashitaka et al., 2012). NST is a neuropeptide that is involved in pain transmission,
learning, and memory. The anti-inflammatory effect of NST was abolished in NIPSNAP1
deficient mice. A later study by the same group reported that NIPSNAP1 deficiency exacerbates
inflammatory pain (Okamoto et al., 2016), possibly through an NST independent mechanism.
Furthermore, they found that NIPSNAP1 expression is controlled by cAMP-protein kinase A
signaling pathway induced by Prostaglandin E2 (PGE2).

It has been reported that NIPSNAP1 and -2 regulate LPS induced, NF-kB-mediated
proinflammatory cytokine production (Yamamoto et al., 2017). Clarithromycin (CAM) is a
macrolide antibiotic that suppresses the production of IL-6 and IL-8 proinflammatory cytokines.
Interestingly, NIPSNAP1 and -2 and very long-chain acyl-CoA dehydrogenase (VLCAD) were
found to be interacting partners of CAM. Knocking down NIPSNAP1 and -2 at the cell line level
suppressed IL-6 and IL-8 cytokines production. This suppression is mediated through the activity
of NF-kB, since the transcription activity of LPS induced NF-kB was reduced in NIPSNAP1 and
-2 deficient cells. No significant reduction in IL-6 and IL-8 cytokines levels were observed in
VLCAD deficient cells. These results suggest that NIPSNAP1 and -2 play a major role in
modulating inflammatory responses (Yamamoto et al., 2017).
Both NIPSNAP1 and VLCAD appear to be involved in inflammatory modulating
pathway. A microarray study revealed that NIPSNAP1 and VLCAD expression levels were
altered in G protein-coupled estrogen receptor (GPER) knockout male mice (Wang et al.,
2017). GPER is involved in glucose and lipid homeostasis as well as inflammation (Oliveira et
al., 2017). It was reported that the activation GPER by its agonist, G1 has an anti-inflammation
response in dopaminergic (DA) neurons by protecting neurons from MPP+ and MPTP
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neurotoxins. Oliveria et al (2017) showed that GPER activation by G1 decrease phagocytic
activity, expression of inducible nitric oxide synthase and release of nitric oxide (NO) induced
by LPS.
Notably, our group has previously shown that NIPSNAP1deficiency decreases brain size
and increases neuronal death, suggesting a potent role of NIPSNAP1 in neuroprotection (Baggett
A. K 2016).

Significance
Oxidative stress resulting from mitochondrial dysfunction has been strongly associated
with Alzheimer Disease and a variety of other neurodegenerative diseases (Castellani et al.,
2002). Elevation in oxidative damage has been associated with Aβ deposition (Butterfield,
2002). It has been reported that Aβ interacts with dehydrogenases like ABAD (Aβ-binding
alcohol dehydrogenases) in the mitochondria and that interaction induces a change in the NAD
binding site in ABAD (Lustbader JW, 2004). ABAD seems to have a detoxifying effect on
aldehydes such as 4-hydroxy-2-nonenal (4-HNE), a product of lipid peroxidation. The ABAD
detoxification effect was hindered by Aβ interaction, resulting in the elevation of ROS
production and thus mitochondrial dysfunction (Murakami et al., 2009). Studies in our lab
further link AD to mitochondrial dysfunction through APP where it was shown that AICD
directly interacts with uMtCK and NIPSNAP1NIPSNAP1 which are located in mitochondria.
Furthermore, NIPSNAP1 interacts with branched-chain α-ketoacid dehydrogenase
complex (BCKDC) and pyruvate dehydrogenase complex (PDC) complexes (Nauyital et al,
2010). These interactions suggest that NIPSNAP1 may have a regulatory role in mitochondrial
metabolism. In line with the above observation, preliminary experiments done in our lab have
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shown that NIPSNAP1 can directly bind to NAD+ and NADP+ with slightly higher binding
affinity to NAD+ (Figure 1 unpublished data). In addition, bioinformatics analysis revealed that
NIPSNAP1 expression is highly associated with mitochondrial genes that are components of
dehydrogenases complexes such as NADH-Qxidoreductase complex, Malate dehydrogenase and
pyruvate dehydrogenases (unpublished data). These data suggest that NIPSNAP1 might be a
subunit of multiple dehydrogenases complexes and have led to the hypothesis that NIPSNAP1
regulates NAD+ and NADH levels through the interaction with dehydrogenases enzymes like
PDH. Interestingly, liver metabolic analysis of NIPSNAP1 KD mice in our lab revealed a
significant elevation in NAD+ levels and reduction in NADH levels is compared to WT (Figure
2, Ghoshal et al., 2014). The high NAD+/NADH ratio suggests an active generation of ATP

through oxidative phosphorylation (OXPHOS). Harmful reactive oxygen species are expected to
be excessively generated as oxygen is reduced along the electron transport chain in the OXPHOS
pathway. Therefore, cells need to keep an active antioxidant defense system to neutralize ROS
through reduced glutathione. In fact, Ghoshal et al. showed that NIPSNAP1 deficiency in liver
resulted in lower levels of reduced glutathione (GSH) compared to wild-type liver controls
(Figure 3, Ghoshal et al., 2014). The reduced level of GSH might indicate ROS clearance
machinery is altered in the liver of NIPSNAP1 KO mice, which leads to an elevation in ROS
levels and thus creating an oxidative environment. Therefore, measuring ROS directly in
NIPSNAP1 deficient cells will help in understanding NIPSNAP1 role in mitochondrial
dysfunction
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Figure 1. NAD+/NADP+ Pull-down analysis
Biochemical pull-down experiments show direct binding of purified recombinant
NIPSNAP1 protein to NAD+ and NADP+ immobilized sepharose beads (Source:
Shuhong Qiao, unpublished observations).

Figure 2. NAD levels in NIPSNAP1 KD liver
Liver samples (500 mg) from eight WT and seven NIPSANP1 KD male mice (13–15
months old) were analyzed using liquid and gas chromatography/mass spectrometry
approaches. A significant increase in NAD+ (1.27 FC, p < 0.05) (Source: Ghoshal, S.,
Jones, L., Homayouni, R. (2013). Nipsnap1 deficient mice exhibit altered liver amino acid,
lip and nucleotide metabolism. Metabolomics 250-258)
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Figure 3. Levels of glutathione metabolites in NIPSNAP1 KD liver
Liver samples (500 mg) from eight WT and seven NIPSANP1 KD male mice (13–15
months old) were analyzed using liquid and gas chromatography/mass spectrometry
approaches. A significant reduction in GSH (0.63 FC, p< 0.05, Welch’s t test) and
slight elevation in GSSG (1.09 FC, p< 0.12, Welch’s t test) n = 8 WT and n = 7 KD.
(Source: Ghoshal, S., Jones, L., Homayouni, R. (2013). Nipsnap1 deficient mice
exhibit altered liver amino acid, lip and nucleotide metabolism. Metabolomics 250258)

Major Questions
The major aim of this study is to investigate whether NIPSNAP1 deficiency is linked to
mitochondrial dysfunction by directly measuring reactive oxygen species (ROS) levels in
NIPSNAP1 knockdown cells. To address this aim, I developed and validated an shRNA
lentiviral-mediated gene silencing approach to generate a knockdown cell line. I showed that the
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knock-down is effective by assessing NIPSNAP1 protein levels using Western Blot analysis.
Subsequently, I evaluated ROS production in normal and NIPSNAP1 knockdown hepatoma cell
line (Hepa 1-6).

Methods
Cell Culture
HEK293T and mouse Hepatoma (Hepa 1-6) cells were obtained from ATCC (CRL1830)
and maintained in DMEM medium (Sigma, UK) containing 10% FCS (Sigma, UK), 1%
100 μg/mL streptomycin/ penicillin (Gibco).

shRNA Lentivirus Construction
An online tool (sirna.wi.mit.edu) was used to design shRNAs that target three different
exonic regions of NIPSNAP1 (Mus Musculus, NM_008698). The following parameters and
filtering methods were selected to ensure the effectiveness of the shRNA sequences: (1) The
length of the siRNA sequence was designed to be 21 nucleotides long following the pattern of
AA(N19), incorporating a 3’ overhang Uracil dinucleotides Figure 4 (B). (2) Only sequences with
less than 50% G-C content were considered. (3) The siRNAs were further filtered by eliminating
sequences with 4 or more nucleotides repeats. (4) Only siRNAs that bear a less stable 3’- AT rich
ends were searched against the mouse genome using BLAST to ensure that the siRNAs were
specific to NIPSNAP1 sequence and to reduce off target binding. Using this process, three
potential siRNA target sequences were selected for cloning into expression vector. The online
tool analysis are shown in Figure 8.
Three sets shRNA oligos were designed to include the sense and anti-sense strands of the
siRNA sequence centered by shRNA loop with the following sequence: CTCGAG. In addition,
12

AgeI and EcorRI overhang restriction sites were added to the 5’- end and 3’- end of the oligo,
respectively. An illustration of the designed oligos is shown in (Figure 5). The oligos were
ordered from integrated DNA technologies (IDT).
Each set of the shRNA oligos were annealed following conditions: 5 L of (20 M)
forward (FW) oligo and 5 L of (20 M) reverse (RV) oligo were mixed in 5 L 10xNEBuffer 2
(NEB #B7202) and the mixture was brought to 35 L by addition of water. The reaction was
incubated at 950 C for 4 mins using a thermocycler machine. Then, the reaction was placed in
700 C water bath and allowed to slowly cooled to room temperature for several hours.
Approximately 2 g of pLKO.1 puro (Addgene plasmid # 88453) expression vector was
digested with 1 L AgeI (NEB # R0552) and 1 L EcroRI (NEB # R3101) at 370 C overnight.
The digested vector was purified with PCR purification kit from Qiagen (Cat No. 28104). The
annealed oligos at a concentration of 4 pmole/ l were ligated into 50 ng of digested pLKO.1
puro using T4 DNA ligase (NEB # M0202S). The reaction was incubated overnight at room
temperature. An illustration of the shRNA constructs is shown in Figure 4. Successful insertion of
shRNAs was confirmed by restriction digestion using. MluI and BamHI restriction enzymes.
MluI site is in between AgeI and EcoRI, which were used to insert the shRNA sequence.
Therefore, MluI should not digest plasmids with shRNA insert. Therefore only BamHI should be
able to digest the plasmid, resulting in single cut and linearization of the plasmid. An illustration
of the restriction digestion screening procedure is shown in Figure 6. Finally, positive clones
were sequenced using the common LKO.1 5’ primer (GACTATCATATGCTTACCGT) to
further confirm shRNA insertion into pLKO.1 vector. Sequencing was performed at UT
Molecular Resource Center.
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Figure 4. Schematic representation of shRNA Lentivirus construction.
(A) Cloning strategy used for ligation of the shRNA oligos into pLKO.1 puro vector. (B) Structure of
the resulting shRNA expressed in lentivirus infected mammalian cells.

Figure 5. Three shRNA sequences that targets mouse NIPSNAP1 at different exonic regions.
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Figure 6. Schematic demonstration of restriction digestion screening for successful cloning
Positive clones were digested by BamHI restriction enzyme, resulting in a single band when run on gel.
Whereas negative clones are digested by both MluI and BamHI, resulting in two bands.

shRNA Lentivirus Packaging and delivery
A general overview of the lentiviral production procedure is shown in (Figure 7). The
lentiviral expression system includes a shuttle vector pLKO (Addgene plasmid # 88453),
packaging plasmids psPAX2 (Addgene plasmid # 12260), and pMD2.G (Addgene plasmid #
12259). shRNA lentivirus particles were produced in 40%–60% confluence HEK293T cells
grown in 10 cm plates using standard calcium phosphate transfection method as follows. Conical
tubes containing 8 ml of DMEM were pre-equilibrated in 37 C incubator for 40 min. while 6.25
g of NIPSNAP1-pLKO lentiviral vector along with 6.25 g of psPAX2 and 3.12 g pMD2.G
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were co-precipitated in 50 l CaCl2 / water solution. Then, 500 l of BES-Buffer (BBS) buffer
was added dropwise to the DNA/ CaCl2 solution. The mixture was added to the pre-equilibrated
media and cells were incubated with this cocktail for 24 hr. Approximately, 48 hr posttransfection, the culture media was collected, filtered with 0.45 um PES syringe filters (Millipore
sigma, SHLP033RS) and concentrated by ultracentrifuge at 21,000 rpm. Then, The virus pellet
was resuspended in 100 l fresh media and stored at -80 C freezer.

Figure 7. Schematic illustration of Lentivirus Packaging and Delivery to Hepa 1-6 cells

Immunoblotting
HEK293T cells were infected with 15 l of concentrated shRNA lentiviruses at 50% confluency.
Cells were supplemented with fresh media after 24hrs of infection. Subsequently, cells were
homogenized in lysis buffer containing 0.05% NP40, 150 mM NaCl, 50 mM Tris-HCl [pH 7.4],
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10% glycerol, EDTA-free protease inhibitor cocktail (Roche) at different time point ranging
from 4 days post infection to 13 days post infection. Protein amounts were quantified using BCA
protein assay kit (Pierce), and equal amount of lysate was mixed with 4x loading dye and
separated by 10% SDS-PAGE. Proteins were transferred onto PVDF membranes and blocked
with 5% nonfat dairy milk for 1 hr at room temperature. Membranes were then subjected to
immunoblot analysis anti-NIPSNAP1 diluted in 5% BSA (Rockland Immunochemicals, 1:
5,000) and Goat Anti-Mouse IgG (abcam, 1: 4,000) antibodies. Quantitative analysis were done
using Chemidoc machine.

Puromycin kill-curve experiments
Hepa 1-6 cells were grown in 12 well-plate to approximately 50% confluency and then
treated with various concentrations of puromycin (0, 0.5, 2.5, and 5 μM). Cells were grown at 37
C and cultured as described above while replenishing the puromycin containing media every 2
days. Cells were monitored under the microscope and cell images were recorded over the course
of 7 days.

Mitochondrial ROS measurements
The mitochondrial superoxide indicator MitoSOX Red (ThermoFisher) was used to
measure ROS production in Hepa 1-6 cells. Approximately 0.12 x 106 cells were seeded in 24
well-plate one day before the experiment so that they are nearly confluent on the day of the
experiment. WT and NIPSNAP1 KD cells were treated with 5μM MitoSOX and incubated for
15mins inside 37 C incubator. Cells were washed twice with Phenol free DMEM media to
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remove un-absorbed and excess MitoSOX. To stimulate ROS production, wildtype and
NIPSNAP1 KD cells were treated with Antimycin A (sigma) (a complex III-specific inhibitor of
the ETC) for 30 mins. Antimycin A treated cells were served as positive control for
mitochondrial ROS generation. Various concentrations of Antimycin A treatments (30, 15, and
5 μM) were examined. Fluorescence intensity was monitored with microplate reader using 530
nm excitation and 620 nm emission wavelengths.

Results
The generation of NIPSNAP1 shRNA lentivirus expression vector
For successful shRNA knockdown, it’s crucial to ensure that the shRNA oligonucleotides
are targeting an effective region of NIPSNAP1. Therefore, I used an online shRNA designing
tool to screen for shRNA targeting regions in mouse NIPSNAP1 coding sequence. Certain
filtering methods and parameters were used to ensure the effectiveness of the oligos as described
in Methods. The insertion of the oligos into pLKO.1 Puro Lentivirus expression vector was
performed as described in methods. An illustration of the construction of shRNA vector is shown
in (Figure 4).
To screen for the successful insertion of shRNA oligos into pLKO vectors, plasmids
isolated from bacterial colonies grown on ampicillin agar plates were digested with MluI and
BamHI . MluI site is located between AgeI and EcoRI. Therefore, the MluI site will be removed
when digesting the plasmid with AgeI and EcoRI. However, BamHI site is downstream the
insertion region. Hence, positive clones can be identified by producing one band due to the
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single cut using BamHI restriction enzyme. The negative clones resulted in two bands due to the
double cuts using MluI and BamHI restriction enzymes. The results of the screening is shown in
Figure 9. To further confirm the shRNA insertion into the vector, positive plasmids identified by

restriction analysis were sequenced using the common LKO.1 5’ primer
(GACTATCATATGCTTACCGT) that is complementary to the human U6 promoter which is
located upstream of the shRNA insertion site. The results from the sequencing of positive clones
for each shRNA construct is shown in Figure 10.

Figure 8. Designing shRNA oligos using online designing tool
The mouse NIPSNAP1 mRNA (accession number: NM_008698.2) was used to search for shRNA oligos using
the online tool sirna.wi.mit.edu. Certain criteria and filtering methods were followed to ensure the specificity
of the design as described in methods.
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Figure 9. Positive insertion of shRNA into pLKO.1 was identified with restriction digestion.
Plasmids isolated from bacterial colonies grown in ampicillin agar plates were digested with
MluI and BamHI and run on an agarose gel to validate ligation and identify positive clones.
Positive clones are identified to result in a single cut and produce one band with high molecular
weight.

Figure 10. Sequencing confirmation of the successful cloning of shRNA into pLKO.1
Positive clones from restriction analysis were sequenced using LKO.1 5’ primer
(GACTATCATATGCTTACCGT) that is complementary to human U6 promoter, upstream of the shRNA
insertion site.
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shRNA lentivirus Infection Efficiency in mouse hepatoma cells
pLKO.3G expression vector which encoded Green Fluorescent Protein (GFP) marker was
used as a positive control to monitor the successful packaging and production of lentivirus
particles. An overview of the process for packaging and delivery into mammalian cell is
illustrated in Figure 5. Hepa 1-6 cells were infected with 15 L of concentrated virus particles
containing pLKO.3G encoding GFP. The cells were examined one day post infection with
confocal microscopy. Around 80% of the cells were successfully transduced and expressed green
fluorescence (Figure 11).

Figure 11. shRNA lentiviral infection efficiency in mouse hepatoma cells
Hepa 1-6 cells infected with 15 µL concentrated pLKO.3G lentivirus. Live
Cells were imaged one day post infection under confocal microscopy using
20X magnification. Viral transduction was monitored by the expression of
green fluorescent protein.
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Determination of optimal Puromycin concentration for selection of transduced Hepa 1-6
cells
pLKO.1 PURO and pLKO.3G vectors contain Puromycin resistance gene. A kill curve
analysis was performed to determine the lowest concentration of Puromycin that selects
transduced Hepa 1-6 cell, while killing all of the non-transduced cells within 7-10 days. The
experiment was monitored visually using an inverted microscope for 7 days (Figure 122). The
optimal concentration was determined to be between 2.5 to 3.5 M Puromycin.

Figure 12. Determination of Puromycin concentration to select transduced Hepa 1-6 cells.
Hepa 1-6 cells were treated with 0, 0.5, 2.5, and 5 µM of Puromycin and cell survival was monitored
over the course of 7-10 days using inverted microscope at 4x magnification. 2.5 µM of puromycin
was the lowest concentration that killed 100% of cells at day 7.
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Knockdown of NIPSNAP1 by lentivirus-mediated shRNA
The efficiency of Sh1, Sh2, and Sh3 lentivirus constructs to knockdown endogenous
NIPSNAP1 was assessed by Western blot analysis. Hepa 1-6 cells were infected with 15 l of
concentrated virus particles that expressed pLKO.1 encoding either sh1, sh2, or sh3. Cells were
treated with 3.5 M Puromycin for seven days to enrich the population of transduced cells.
Whole cell lysates were collected at various time points ranging from 2 days post infection to 13
days post infection. All three shRNA constructs were able to knockdown NIPSNAP1 with
different efficiencies (Figure 13). Western blot analysis showed that Sh1 is the most effective
shRNA construct to knockdown NIPSNAP1. Sh1 transduced cells showed around 85% reduction
in NIPSNAP1 protein level. Whereas, sh2 was slightly less effective and showed a knockdown
efficiency near 75%. Sh3 was the least effective shRNA with around 40-45% reduction in
NIPSNAP1 protein level. Relative quantitative analysis was by normalizing the intensity of each
band to the intensity of Actin, used as a loading control. pLKO.1 was used a negative control and
knockdown percentage was estimated by measuring the ratio of each shRNA normalized
intensity to pLKO normalized intensity (Figure 13 B).
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Figure 13. shRNA lentivirus-mediated Knockdown of NIPSNAP1
(A) NIPSNAP1 protein levels were detected by Western blot analysis in two independent groups of Hepa 1-6
cells that were transduced with either pLKO control, sh1, sh2, or sh3 and then selected with Puromycin for 710 days. Whole cell lysates were collected 10 days post infection in Group1 and 13 days post infection in
Group2. Group 1 and 2 represents separate experiments. (B) Quantitative representation of Western blot
results.

NIPSNAP1 is a stable protein
Western blot analysis of hepa 1-6 whole cell lysates collected at different times postinfection showed a time-dependent gradual reduction in NIPSNAP1 protein levels (Figure 14).
shRNA1 showed a weak reduction of NIPSNAP1 protein level at four days post-infection, but
showed a robust decrease (~6-fold) at 10 days post-infection, which persisted to 14 days postinfection. On the other hand, sh2 knockdown showed a 2 fold reduction at four days and
progressively reduced NIPSNAP1 protein levels at 10 days and 14 days post-infection, reaching
a knockdown level close to sh1. Although sh3 showed an initial knock-down at 4 days postinfection, the level of Nipsnap1 stayed the same (around 2-fold decrease) at 10 and 13 days.
These results demonstrate that sh1 is the most efficient construct to knock-down NIPSNAP1
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protein levels, but the knock-down takes time to develop, presumably due to the stability of
NIPSNAP1 protein in the mitochondria.

Figure 14. Gradual reduction of NIPSNAP1 protein level with time
Immunoblotting and quantification of NIPSNAP1 levels in Hepa 1-6 cells transduced with three
different shRNAs with time. Cells were infected with pLKO(control), Sh1, Sh2, and Sh3 lentiviruses
and grown in the Puromycin. Whole cell lysates were collected at 4 days (A), 10 days (B) and 14 days
(C) post-infection and used for immunoblotting analysis using NIPSNAP1 antibody to confirm
knockdown.

NIPSNAP1 deficiency lowers growth rate but has no effect on cells health
Routine visual examination of transduced cells under the microscope indicated that
knockdown cells had a slower growth rate compared to pLKO transduced cells. No noticeable
changes in the morphology of the cells was observed. The effect of NIPSNAP1 deficiency in
growth rate needs to be further investigated in future studies. Figure 15.

25

Figure 15. Cell density after shRNA mediated NIPSNAP1 knockdown
Microscopic assessment of the confluency and health of hepa 1-6 cells after virus transduction of pLKO.1
(control) compared to sh1, sh2 and sh3 constructs.

NIPSNAP1 deficiency reduces Reactive Oxygen Species levels in mouse Hepa1-6 cells
To evaluate the role of NIPSNAP1 in oxidative stress, the production of ROS was
measured in WT and NIPSNAP1 knockdown Hepa 1-6 cells. Puromycin selected cells were
treated with MitoSOX and the ROS levels detected by fluorescence detection using a microplate
reader. The signals were normalized to cells that were not treated with MitoSOX to eliminate
nonspecific background signal. Data were collected from two separate experiments and the
average values were graphed and presented in Figure 16. ROS production was induced with
Antimycin A (a complex III inhibitor in the electron transport chain) in order to establish a
baseline for comparing signals obtained from knockdown and WT cells. The data show that ROS
levels are reduced in knockdown cells compared to pLKO control (Figure 16). At lower
concentration of Antimycin (5 uM), we observed a proportional relationship between NIPSNAP1
protein levels (Figure 12) and ROS levels. ROS levels were lower in cells with sh1 (Figure 16 A),
which showed the most robust reduction in NIPSNAP1 protein levels. However, at higher
concentration of Antimycin (30uM), the ROS decrease was similar for all three shRNA
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constructs (Figure 16 C). sh1 construct showed approximately 50% reduction of ROS at both
concentrations of Antimycin.

Figure 16. Assessment of reactive oxygen species (ROS) production in NIPSNAP1 deficient cells
pLKO control and NIPSNAP1 knockdown cells were incubated with MitoSOX red and then treated
with 0 uM, 5 uM and 30 uM Antimycin followed. After treatment ROS levels were measured using
microplate reader..

Discussion
In this study, I aimed to establish a new approach to knockdown NIPSNAP1 expression
in cultured cells. Although our lab had previously generated a knockdown (KD) mouse model
using a retroviral gene trap strategy (Ghoshal et al., 2014), knocking down NIPSNAP1 in cell
culture will offer a simple and homogenous system where we can tightly regulate NIPSNAP1
levels or express mutated forms of NIPSNAP1 protein to investigate its molecular and cellular
functions. For example, it is much easier to study the effect of NIPSNAP1 on a particular cellular
process such as ROS production under acute treatment conditions and then further map the
specific domains of NIPSNAP which are required for this function. These types of studies are
difficult to perform in mouse models for several reasons. Primarily, it is difficult to conduct
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experiments using mutated versions of NIPSNAP1 in animal models. Moreover, since in the
mouse model NIPSNAP1 has been knocked-down in germline, the animal may have
physiologically compensated for the lack of NIPSNAP1 expression by adulthood. Indeed, a
recent paper has shown that NIPSNAP2 can functionally compensate for NIPSNAP (Abudu et
al., 2019). Lastly, acute treatments are difficult to perform in animal models.
The generation of knockdown cell line was done using shRNA lentiviral-mediated gene
silencing approach. shRNA was used instead of siRNA approaches due to its prolonged duration
of interference. Unlike siRNA methods that transiently transfect into the cytoplasm, lentiviral
delivery of shRNA integrates the expression vector in the genome of the cell and produces longterm expression inside the nucleus. Using the cell’s machinery shRNAs are constantly
transcribed and then processed by DICER to form the mature siRNA that interacts with mRNA
silencing machinery in the cytoplasm. Sustaining the knockdown for longer periods will enable
us to select for and enrich knockdown cells and test multiple factors in the same experiment. In
addition, viruses are more efficient in delivering DNA material and can infect all mammalian
cell types including primary neurons. This approach will set the stage for future experiments to
validate the studied mechanism in multiple cell lines and in primary cultured cells. It is worth
noting that we used lentivirus rather than adeno viruses because they are easier to pack and
produce. In addition, lentiviruses are more suitable for infecting cultured cell whereas
adenoviruses are widely use to infect cells in vivo.
Not all shRNA molecules effectively knock-down the target protein. Thus, in order to
maximize the chance of knocking down NIPSNAP1, I designed three shRNAs that target
different regions of NIPSNAP1 mRNA sequence. It’s suggested that shRNAs with 3’
overhanging Uracil dinucleotides are more effective in silencing their target genes (Elbashir et
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al., 2001). In fact, this notion was consistent with my knockdown results. Two of the shRNAs
(Sh1 and Sh2) were able to effectively reduce NIPSNAP1 level in Hepa 1-6 cells by 80% (Figure
13 B). Both of these shRNAs contained 3’ overhanging Uracil dinucleotides. In contrast, Sh3

lacked the 3’ overhanging Uracil dinucleotides and did not reduce NIPSNAP1 levels by as much
(Figure 13 B). In addition, a designing error was discovered in sh3 sequence that resulted in one
base pair mismatch toward the 5’ end of the shRNA (Figure 10). We expect this mismatch error
decreased the shRNA targeting specificity which also contributed to the decrease effectiveness of
sh3.
There is accumulating evidence that suggests NIPSNAP1 is an important regulator of
cellular energy metabolism. Therefore, we expected to observe significant changes in the growth
and morphology of NIPSNAP1 deficient cells compared to WT cells. Based on preliminary
visual observations, the morphology of Hepatoma cells were not affected by knocking down
NIPSNAP1. However, NIPSNAP1 deficient cells showed a slightly lower density during routine
observations (Figure 15). Further investigation is needed to determine if the lower density is due
to a slower growth rate, possibly caused by lowering energy metabolism.
We observed a time-dependent reduction in NIPSNAP1 protein levels in Hepa1-6 cells
infected with sh1, sh2, and sh3 (Figure 14). The protein concentrations were reduced
significantly by day 10 post-infection compared to day 4. This observation suggests that
NIPSNAP1 might have a slow turnover rate especially under cellular stress. Prolonged turnover
rate is well known proteins that are very essential for the cell homeostasis. Posttranslational
modifications like ubiquitination and phosphorylation regulate protein’s activity and can change
its kinetic properties in response to various stimuli. At the transcription level, NIPSNAP1
expression is induced by Prostaglandin E2 (PGE2) through cAMP-protein kinase A signaling

29

pathway in response to inflammation (Okamoto et al., 2016). Additionally, NIPSNAP1 is
downstream target of PAK1 kinase and the depletion of PAK1 down regulates NIPSNAP1 level
(Motwani et al., 2013). To gain more insight about NIPSNAP1 stability, a more detailed study is
needed to investigate its turnover rate as well as its transcriptional regulation.
An important indication of mitochondrial dysfunction is the excessive production of
reactive oxygen species (ROS), which are highly reactive molecules with un-paired electron.
ROS is generated in mitochondria as oxygen is reduced along the electron transport chain. ROS
are also produced as intermediates in different enzymatic reactions (Groge, 2002). The constant
production of ROS intermediates is controlled enzymatically by antioxidants such as superoxide
dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx). Superoxide anions are
converted to hydrogen peroxide by SODs. Under normal conditions, glutathione peroxidase and
catalase will convert hydrogen peroxide to water molecules. The oxidized form of glutathione is
converted back to reduced state through NADPH dependent reaction (Groge, 2002).
Our group has previously reported that the absence of NIPSNAP1 in the liver resulted in
oxidative stress as indicated by a significant reduction in the level of the reduced glutathione
(GSH) (Ghoshal et al., 2014). More importantly, in the same study Ghoshal et al (2014) reported
an elevation of the tryptophan metabolite 3-indoxyl sulfate (IS), which is implicated in oxidative
stress by inducing ROS production (Fujii et al. 2011). IS induces ROS production by
upregulation the expression of NADPH oxidase (Muteliefu et al., 2012). In light of this finding,
we predicted to observe an elevation in the mitochondrial ROS levels in the mouse liver cell line,
Hepa 1-6. Complexes I and III of the mitochondrial electron transport chain (ETC) are the major
sites of the reactive oxygen superoxide production (Groge, 2002). Therefore, I used a fluorogenic
dye called MitoSOX Red to evaluate ROS production, since MitoSOX is a hydroethidine that
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can be oxidized by superoxide to form ethidium, which fluoresces when it binds to DNA
(Lebedeva et al., 2009). To our surprise, our data indicate a significant reduction in ROS levels
after shRNA mediated NIPSNAP1 knockdown compared to pLKO.1 control cells (Figure 16).
More importantly, the reduction in ROS level correlated with knockdown efficiency of the
different shRNA constructs. That is, the most efficient shRNA showed more severe reduction in
ROS level.
The observed reduction of ROS by the depletion of NIPSNAP1 was confirmed by
inducing ROS production with Antimycin A, an inhibitor of the mitochondrial electron transport
chain (ETC). Antimycin A inhibits the flow of the electrons in the ETC by binding to
cytochrome b subunit of complex III and preventing it from interacting with electron carrier
coenzyme Q (Huang et al., 2006). Although we recorded a dose-dependent increase in ROS
production in cells treated with different concentrations of Antimycin A (Figure 16 B-C),
knockdown cells treated with Antimycin A produced less ROS compared to the control pLKO
Antimycin treated cells.
Collectively, Goshal et al., (2014) findings and my current results suggest that
NIPSNAP1 seems to regulate ROS production in inconsistent manner in liver cells. It’s worth
noting that the Glutathione level were measured in primary liver tissues isolated from
NIPSNAP1 deficient mice (Ghoshal et al., 2014), whereas I measured ROS levels in liver cellline under acute conditions. It is possible that ROS production in whole animals is under the
regulation of different pathways due to the crosstalk between heterogenous cells. It is also
possible that in animals, NIPSNAP1 deficiency is compensated by NIPSNAP2 to some degree
and has slightly different effects on ROS production
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We proposed that NIPSNAP1 can regulate energy metabolism because of its interaction
with dehydrogenase complexes like pyruvate dehydrogenase (Nauyital et al, 2010). Consistent
with those observations, our lab has previously shown that NAD/NADH ratio is increased in
NIPSNAP1 KD liver mice compared to WT ( Ghoshal et al., 2014). Which should result in lower
generation of ROS. In line with that, I found a reduction in ROS generation in NIPSNAP1
knockdown liver cell line. This reduction might indicate an impairment in the ETC system and
thus less amount of NADH is entering the mitochondrial respiratory chain reaction and less ROS
will be generated as byproducts. The accumulation of NAD might indicates that NIPSNAP1
deficiency is inhibiting the conversion of pyruvate to acetyl CoA, since NAD is reduced to
NADH during this process. Furthermore, Ghoshal et al., (2014) liver metabolomics data indicate
that glycolysis intermediates are downregulated in NIPSNAP1 deficient liver. Collectively, the
increased levels of NAD along with the reduction in glycolysis intermediates can suggest that
gluconeogenesis is occurring in liver when NIPSNAP1 is depleted. It’s worth to mention that
gluconeogenesis usually occurs in liver during fasting state, where the liver is required to
produce glucose through gluconeogenesis and ketone bodies by metabolizing fatty acids to
supply energy consuming organs like the brain (Zhang et al., 2014). Thus, NIPSNAP1 deficiency
seems to imitate starvation state where the liver can be stimulated to undergo gluconeogenesis to
support other organs with energy. A proposed model of energy metabolism pathway in
NIPSNAP1 deficient liver is shown in Figure 17 where levels of altered metabolites are
demonstrated in the pathway.
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Figure 17. Overview of energy metabolism in Nipsnap1 deficient liver.

It is worth to include in this discussion that ROS production is reduced when the tumor
suppressor p53 is repressed. In addition to its function as a transcription factor, p53 is implicated
in various cellular processes like mtDNA maintenance, apoptosis, DNA repair, and cell cycle
arrest (Vaseva et al., 2009). It has been reported that mitochondrial and cellular superoxide levels
are reduced in p53 deficient cells, where cellular hydrogen peroxide levels are increased
(Lebedeva et al., 2009). It is worth noting that glutathione peroxidase reduces hydrogen peroxide
to water molecules by catalyzing the oxidation of glutathione and our lab has previously shown
that NIPSNAP1 depleted cells exhibits a low level of reduced glutathione. Thus, NIPSNAP1
might function similar to p53 in regulation ROS homoeostasis. It would be very beneficial in the
future to measure hydrogen peroxide levels in NIPSNAP1 deficient cells to further elucidate
NIPSNAP1 role in regulating ROS production.
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In conclusion, we proposed that NIPSNAP1 is an important regulator of cellular
processes especially in cellular metabolism, but more experiments are still needed to further
elucidate the molecular function of NIPSNAP1 and its precise role in the mitochondria. The
knockdown system that was developed in this study will provide new tools to enhance our
understanding of NIPSNAP1 function at the molecular level.
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